GlobeNewsWire
01 Dec 2025, 12:30 UTC · 50w ago
Biogen and Stoke Therapeutics Announce Presentations at the 2025 American Epilepsy Society Annual Meeting
Impact · against what's priced in
The announcement of disease-modifying potential for zorevunersen, supported by new EEG and four-year clinical data, provides a positive catalyst for both Biogen and Stoke Therapeutics. The transition from simple seizure management to potential disease modification increases the long-term valuation ceiling for the drug ahead of the Phase 3 EMPEROR study results.
- STOK+0.60
No priced-in read yet





